5. Progressive supranuclear palsy Clinical trials / Disease details

Clinical trials : 95 / Drugs : 119 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03058965 (ClinicalTrials.gov)	November 29, 2016	12/1/2017	Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain	Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers	Alzheimer Disease;Healthy Volunteers;Progressive Supranuclear Palsy	Drug: [18F]MNI-958;Drug: [18F]Florbetapir;Drug: DaTscan	Molecular NeuroImaging	NULL	Completed	50 Years	90 Years	All	12	Early Phase 1	United States
2	NCT03080051 (ClinicalTrials.gov)	August 2016	12/1/2017	Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain	Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers	Progressive Supranuclear Palsy;Alzheimer Disease;Healthy Volunteers	Drug: [18F]MNI-952;Drug: [18F]Florbetapir	Molecular NeuroImaging	NULL	Completed	18 Years	90 Years	All	6	Early Phase 1	United States